Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Updated results of the phase II ALTER-H004: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of recurrence after surgery.
Authors
Zheng Wu
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Zheng Wu , Zheng Wang , Lei Zhang , Xiaojing Song , Xilin Du , Kai Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04213118
DOI
10.1200/JCO.2022.40.4_suppl.445
Abstract #
445
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.
First Author: Xianhai Mao
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection.
First Author: Xianhai Mao
Poster
2020 ASCO Virtual Scientific Program
Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Interim results from a muticenter prospective cohort study.
First Author: Jin-hong Chen
Poster
2024 ASCO Annual Meeting
Utilization of tumor-informed circulating tumor DNA in detecting minimal residual disease and guiding adjuvant therapy in liver cancer.
First Author: De-Zhen Guo